Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Indacaterol/mometasone - Novartis

Drug Profile

Indacaterol/mometasone - Novartis

Alternative Names: Mometasone furoate/indacaterol acetate; Mometasone/indacaterol; QMF-149

Latest Information Update: 14 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis; Schering-Plough
  • Developer Merck & Co; Novartis
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Bronchodilators; Glucocorticoids; Indans; Pregnadienediols; Quinolones; Small molecules
  • Mechanism of Action Arachidonic acid inhibitors; Beta 2 adrenergic receptor agonists; Glucocorticoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preregistration Asthma
  • Discontinued Chronic obstructive pulmonary disease

Most Recent Events

  • 30 Sep 2019 Efficacy and adverse events data from a phase-III PALLADIUM trial in Asthma released by Novartis
  • 30 May 2019 Preregistration for Asthma (Adjunctive treatment) in European Union (Inhalation), prior to May 2019
  • 30 May 2019 European Medicines Agency (EMA) accepts NDA for indacaterol/mometasone for Asthma for review, prior to May 2019
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top